<b>Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration – a Danish Cohort Study</b>

<p dir="ltr"><b>Objective</b></p><p dir="ltr">To determine patient characteristics and dose titration patterns of real-world Wegovy® (semaglutide) users.</p><p><br></p><p dir="ltr"><b>Research Design and Methods</b></p><p dir="ltr">Population-based cohort study including Danish adults who filled Wegovy® from December 12^th, 2022, to December 31^st, 2023. Outcomes were patient characteristics, prescriber type and dose titration patterns.</p><p><br></p><p dir="ltr"><b>Results</b></p><p dir="ltr">We identified 110,748 individuals (median age 49 years; 70% female) filling 773,708 prescriptions for Wegovy®. General practitioners initiated treatment in 86%. Common comorbidities included hypertension (30%), dyslipidemia (17%) and arthrosis (17%). Only 13% reached the maximum dose of 2.4 mg by their 5^th prescription, while 5.7% stopped after the first prescription. Few users (10%) followed recommended dose increases every four weeks. Overall, 25% filled at least one prescription of 2.4 mg, while 33-48% continued with the 1.0 mg dosage from the fourth prescription onwards.</p><p><br></p><p dir="ltr"><b>Conclusions</b></p><p dir="ltr">Real-world Wegovy® users generally resembled trial participants but few follow the dose titration schemes tested in pre-market clinical trials.</p><p><br></p>